Business Wire

Traxens Receives Frost & Sullivan’s Technology Leadership Award for Revolutionizing Ocean Freight

Share

Traxens, a company providing high-value data and services for the supply chain industry, announces today that it has received the prestigious Frost & Sullivan Technology Leadership Award for its novel smart container-tracking Internet of Things (IoT) solution for various industries, including maritime. In addition to the award, Frost & Sullivan also published an in-depth report, ‘Disruptive Innovations in the European Logistics industry,’ which includes analysis of Traxens and its leadership in the field of smart containers.

Traxens’ Internet-of-Big-Things solution is based on a patented, breakthrough technology that enables access to the most comprehensive, precise and timely data for managing assets in transit anywhere in the world. This technology brings improved efficiency and security, greater transparency, and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain.

Traxens’ offering has been recognized for providing invaluable insight to key industry players in the global supply chain market by producing, qualifying, enriching and certifying real-time data.

Traxens offers its cloud-based services but also its own telematics devices, which were developed to address the exact data needs in this segment. Thanks to this end to end solution, Traxens can provide tailored real-time data to all of its customers. Its system has been designed to enable seamless integration with smart devices to ensure flexibility by gathering data.

Traxens devices utilize a patented IoT LowPower mesh network to increase visibility and optimize cellular or satellite network access. Traxens’ IoT platform uses a global positioning system and cellular networks in order to offer full global coverage and transfer data from even the most remote places. Data is sent to Traxens’ IoT platform which handles a vast amount of data from multiple sources. This platform can analyze, manipulate, and convert the data into valuable insights to enable time-sensitive, data-driven decisions, which are key in today’s fast-changing business ecosystems.

“We are thrilled to be receiving this prestigious award from Frost & Sullivan,” said Jacques Delort, CEO of Traxens. “This proves that the company is going in the right direction and is poised to transform the global supply chain industry through state-of-the-art IoT and Big Data services, which can make processes much more efficient for key industry players.”

“Traxens’ solution enables customers to reduce the shipping cost per container per voyage. Moreover, the company goes the extra mile by reducing cargo loss, packaging costs, damaged goods, theft, pilferage, tampering, fraud and counterfeiting, thereby saving billions of euros annually for customers,” said Suriya Anjumohan, Transportation & Logistics Industry Analyst of Frost & Sullivan. “Data delivered by Traxens enables a multitude of supply chain efficiencies enhancing client satisfaction, expediting customs clearance, ensuring process compliance and leading to better insurance and financing agreements."

The international shipping industry is responsible for the transport of approximately 90% of world trade. There are over 50,000 merchant ships transporting cargo all over the world. This generates an estimated annual income of over half a trillion US dollars in freight rates.

Leading consultancy firm Frost & Sullivan recognizes the best of the industry every year at its annual Technology Leadership Awards ceremony, which will take place in London on July 10th.

Traxens already works with two leading shipping companies worldwide and is conducting trials of its equipment in major European ports. It has signed dozens of contracts with BCOs (Beneficial Cargo Owners).

ABOUT TRAXENS

Traxens generates, collects, consolidates, enriches, and transforms logistics asset data into actionable insight. The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers.

www.traxens.com

TRAXENS SAS
Bâtiment C, 15 rue Marc Donadille
Lieu-dit Les Baronnies - 13013 Marseille

 

SIRET : 750 626 871 00040
Tel : 04 84 52 55 63 - Fax : 04 84 52 55 63
www.traxens.com

Contact information

PRESS CONTACT:
Géraldine Saunière
DIRECTOR OF COMMUNICATIONS

Mail: g.sauniere@traxens.com
Tel: +33 695 915 899

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu